Sugi Predict

Sugi Predict / Compounds / SCHEMBL2376378

SCHEMBL2376378

SCHEMBL2376378

CN1CCN(C(=O)Cc2ccc(Br)cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ HPGD P15428 2/20 0.71
▸ NPC1 O15118 2/20 0.71
▸ MAPT P10636 5/20 0.68
▸ ALDH1A1 P00352 5/20 0.64
▸ HTT P42858 4/20 0.62
▸ LMNA P02545 2/20 0.62
▸ GAA P10253 1/20 0.59
▸ ALOX12 P18054 1/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ RAB9A P51151 1/20 0.58
▸ KDM4E B2RXH2 1/20 0.57
▸ GPR183 P32249 2/20 0.56
▸ DUSP3 P51452 1/20 0.53
▸ PTPN5 P54829 1/20 0.53
▸ PTPN11 Q06124 1/20 0.53
▸ POLB P06746 2/20 0.53
▸ HSD11B1 P28845 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10195746 0.85 MEN1 (0.69) SMN1; SMN2HPGDMAPTALDH1A1LMNA
SCHEMBL15301122 0.84 HPGD (0.90) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL2646798 0.84 HPGD (0.96) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL2379004 0.84 GPR183 (0.56) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL2378718 0.84 HSD11B1 (0.72) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL2747321 0.83 MAPT (0.68) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL4548020 0.83 POLB (0.69) SMN1; SMN2MAPTALDH1A1HTTMEN1
SCHEMBL15134817 0.83 MAPT (0.68) SMN1; SMN2HPGDMAPTLMNAGAA
SCHEMBL14261406 0.83 MAPT (0.68) SMN1; SMN2HPGDNPC1MAPTALDH1A1
SCHEMBL31335307 0.83 HPGD (1.00) SMN1; SMN2HPGDNPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2023-11-02 — — US disclosed
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 — — EP disclosed
CN-101094848-B Organic compounds NOVARTIS AG 2013-03-13 — — CN disclosed
EP-2155201-B1 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2012-08-01 — — EP disclosed
US-8193189-B2 Quinoxaline derivatives as tyrosine kinase activity inhibitors NOVARTIS AG (CH) 2012-06-05 — — US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 — — US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 — — US disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 — — US disclosed
US-20100168062-A1 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors NOVARTIS AG 2010-07-01 — — US disclosed
EP-2155201-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES Novartis Ag (CH) 2010-02-24 — — EP disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 — — US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 — — EP disclosed
EP-2064212-A1 PYRROLO ISOQUINOLINES AS KINASE INHIBITORS Novartis AG (CH) 2009-06-03 — — EP disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 — — EP disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 — — WO disclosed
WO-2008025512-A1 PYRROLO ISOQUINOLINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2008-03-06 — — WO disclosed
CN-101094848-A Organic compounds NOVARTIS AG (CH) 2007-12-26 — — CN disclosed
EP-1833816-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Novartis AG (CH) 2007-09-19 — — EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 SMN1; SMN2 3323/4885HPGD 3302/4885NPC1 2284/4885
US-20100168062-A1 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors JAK2, JAK1, JAK3 SMN1; SMN2 4124/4885HPGD 1877/4885NPC1 4739/4885
US-20110263560-A1 Organic Compounds REN, ACE, OTC SMN1; SMN2 2243/4885HPGD 343/4885NPC1 2742/4885
US-20090312304-A1 ORGANIC COMPOUNDS REN, ACE, PIGO SMN1; SMN2 2488/4885HPGD 225/4885NPC1 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.